Study of outcomes in people with Waldenström’s disease
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at medical records to understand what outcomes happen in people with Waldenström’s disease and how well certain factors predict those outcomes. It’s mainly about using past and planned follow-up data, which may help improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Waldenström’s disease (meeting the study’s diagnostic standards).
- Your medical team has follow-up information available until at least Jan 1, 2020.
- You can be followed at least once per year until 2024 (as planned by your study center).
- You must provide your written consent to join this study.
- You do not have another long-term blood cancer besides Waldenström’s disease. (This includes careful checking for related conditions like certain lymphomas).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.
This study looks at bone marrow stem cells in people with Waldenström macroglobulinemia (WM). It aims to understand how these cells work and may help improve future treatments for WM.
This study looks at “hyperviscosity,” meaning very thick blood, in people with Waldenström macroglobulinemia (WM). Your results may help doctors better understand who needs treatment and what tests should be used, even if thick blood is not found.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
This Phase 2 study tests a treatment plan that starts with rituximab plus VRD (bortezomib, and reduced-dose drugs in the VRD group), then uses lenalidomide for maintenance to help control Waldenstrom’s macroglobulinemia. It may help people who need treatment because their disease is measurable.
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Hear when a new Waldenstrom's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.